Form 4 for BSX Boston Scientific
Accepted 2024-01-10 00:00:00 ET · period of report 2024-01-09 · accession 0001225208-24-000738 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-10 | 2024-01-09 | BSX | Mirviss Jeffrey B. | EVP, Pres, Periph Intervent | S - Sale+OE | $59.25 | -15.2K | 56.6K | -21% | -$898.9K |
| D | 2024-01-10 | 2024-01-09 | BSX | Mirviss Jeffrey B. | EVP, Pres, Periph Intervent | M - OptEx | $16.31 | +15.2K | 71.8K | +27% | +$247.5K |
| D | 2024-01-10 | 2024-01-09 | BSX | Mirviss Jeffrey B. | EVP, Pres, Periph Intervent | M - OptEx | $0.00 | -15.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-09 | S | D | 15,172 | $59.25 | 56,588 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-09 | M | A | 15,172 | $16.31 | 71,760 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-01-09 | M | D | 15,172 | $0.00 | 0 | D | $16.31 · — to 2025-02-23 | 15,172 Common Stock | (F2) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. |